Masonic Cancer Center, University of Minnesota: Fallopian Tube Neoplasms trials
The registry lists 13 Fallopian Tube Neoplasms studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 1 6Phase 2 6No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT05708924Phase 1Results posted
- IP ALT-803 Followed by SQ ALT-803 for Ovarian CancerCompletedNCT03054909Phase 2Results posted
- WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian CancerTerminatedNCT01144442Not applicableResults posted
- Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerCompletedNCT01105650Phase 2Results posted
- Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00903630Phase 1/2Results posted
- Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT00652899Phase 2Results posted
- Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic CancerCompletedNCT00381888Phase 2Results posted
- Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00331422Phase 2Results posted
- Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative MedicineCompletedNCT00293293Not applicableResults posted
- Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerActive, not recruitingNCT06342986Phase 1
- Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal IntCompletedNCT03213964Phase 1
- Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic CancerCompletedNCT00287885Phase 1
- Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00287859Phase 1